Loading
TT
Trillium Therapeutics Inc. Stock: price and insider trades · United States
Trillium Therapeutics Inc.: what insiders have been doing
Trillium Therapeutics Inc. belongs to the Health Care sector. Filings by its managers are published through SEC (Form 4). Trillium Therapeutics Inc. has had no insider filing for more than a year; the last one goes back to 19 November 2021.
Over the whole record (from 2021), the tally stands at no purchases and 47 sales.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
102
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€4M
47 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2020FY ended December 2020 · cache
Income statement
Revenue131.8k
Net income-52.8M-40098.6% margin
Last declaration on 19 November 2021
Declarations102 total
75 sharesCommon SharesSEC:0001104659-21-141749:0
5,736,363 shares0Common SharesSEC:0001209191-21-065762:0
3,646 shares@ US$9.005.6% of flowCommon SharesSEC:0001062993-21-006419:1
3,646 shares@ US$0.303933.2% of flowCommon SharesSEC:0001062993-21-006419:0
3,646 shares@ CA$9.0014.6% of flowCommon SharesTSXSEDI:3775053
3,646 shares@ CA$0.380.6% of flowCommon SharesTSXSEDI:3775050
3,646 shares@ US$8.274.9% of flowCommon SharesSEC:0001062993-21-005487:1
3,646 shares@ US$0.31533.3% of flowCommon SharesSEC:0001062993-21-005487:0
3,646 shares@ CA$8.2713.4% of flowCommon SharesTSXSEDI:3759142
3,646 shares@ CA$0.380.6% of flowCommon SharesTSXSEDI:3759140
19,198 shares@ US$0.3140.4% of flowCommon SharesSEC:0001062993-21-004511:1
106,698 shares@ US$9.201759.8% of flowCommon SharesSEC:0001062993-21-004511:2
23,802 shares@ US$0.3140.5% of flowCommon SharesSEC:0001062993-21-004511:3
23,802 shares@ US$9.237913.5% of flowCommon SharesSEC:0001062993-21-004511:4
87,500 shares@ US$0.4462100.0% of flowCommon SharesSEC:0001062993-21-004511:0
23,802 shares@ CA$9.237917.4% of flowCommon SharesTSXSEDI:3743786
87,500 shares@ CA$9.201763.6% of flowCommon SharesTSXSEDI:3743780
19,198 shares@ CA$0.380.6% of flowCommon SharesTSXSEDI:3743782
87,500 shares@ CA$0.543.7% of flowCommon SharesTSXSEDI:3743779
19,198 shares@ CA$9.201714.0% of flowCommon SharesTSXSEDI:3743783
23,802 shares@ CA$0.380.7% of flowCommon SharesTSXSEDI:3743785
Common SharesTSXSEDI:3743778
3,646 shares@ US$9.305.6% of flowCommon SharesSEC:0001062993-21-004390:1
3,646 shares@ US$0.31333.4% of flowCommon SharesSEC:0001062993-21-004390:0
3,646 shares@ CA$9.3015.1% of flowCommon SharesTSXSEDI:3741233
25 of 102 declarations
About Trillium Therapeutics Inc.
Trillium Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies for cancer treatment. It concentrates on immunological approaches to enhance patient outcomes.
